Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche Adds e 602 Immunoassay Module To cobas 8000 Platform
Roche said that the product is available in Europe as well as in all countries recognising the CE mark in the Latin America and Asia-Pacific regions. According to
Roche said that the product is available in Europe as well as in all countries recognising the CE mark in the Latin America and Asia-Pacific regions. According to
Biomoda’s CyPath reagents for the early detection of cancers is based on meso-tetra (4 carboxyphenyl) porphine (TCPP), a porphyrin compound that binds to cancer cells and fluoresces under
In a Phase2 pilot study, Itraconazole topical suspension was shown to be effective in the treatment of FOE with no adverse events reported. Fera Pharma is working to
Genentech said that the committee’s vote has no effect on the present availability of Avastin for people with advanced HER2-negative breast cancer in the US. The decision on
The discoveries which were conducted at the University of Texas Houston Medical School and California Department of Public Health, with support from the National Institutes of Health, were
The relationship will allow clients access to both organizations’ core strengths and geographical expertise. The service expansion will be accomplished through mutual referrals, coordinated sales, marketing, and presentation
TPI-287 study includes patients with disease metastatic to the brain as the drug, avoids the multidrug resistant (MDR) efflux pump and has demonstrated in pre-clinical studies its ability
The agreement gives Sysmex a non-exclusive right to sell CellaVision’s products in hematology laboratories worldwide. As of April 1, 2010, the non-exclusive agreement comprises all international markets except
The partnership calls for SDIX to collaborate with Banyan on the development of antibodies and immuno-solutions that include custom monoclonal and polyclonal antibody development, cell line banking and
Biogen Idec posted a net income of $294.6m for the second quarter 2010, or $1.12 per diluted share, compared $144.8m, or $0.49 per diluted share, for the comparable